Kathryn Nash

Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study

Eleonora Scorletti, Lokpal Bhatia, Keith McCormick et al. · Hepatology · 2014 · 306 citations

Pathology, Epa Enrichment, Fatty Liver Disease +18

A single centre experience of liver disease in adults with cystic fibrosis 1995–2006

Kathryn Nash, Michael Allison, Damian McKeon et al. · Journal of Cystic Fibrosis · 2007 · 73 citations · Full text

Cystic Fibrosis 1995–2006, Fibrosis, Hepatic Disorders +12

Determinants of chronic infection with Staphylococcus aureus in patients with bronchiectasis

S. Mawdsley, Kathryn Nash, Paul Cullinan et al. · European Respiratory Journal · 1999 · 69 citations · Full text

Cystic Fibrosis Liver Disease: To Transplant or Not to Transplant?

Kathryn Nash, Jane Collier, Jane French et al. · American Journal of Transplantation · 2007 · 52 citations · Full text

Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease

Eleonora Scorletti, Lokpal Bhatia, Keith McCormick et al. · Contemporary Clinical Trials · 2014 · 44 citations

Obesity, Metabolic Syndrome, Hepatology +9